http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Erdene to Announce Q3 2025 Results on November 4, 2025
-
BeyondTrust Experts Reveal Top Cybersecurity Predictions for 2026 and Beyond
-
Conduent adds GenAI contract analytics to FastCap finance platform
-
Conduent’s FastCap® Integrates GenAI-Powered Contract and Spend Analytics to Boost Financial Performance
-
Green Rain Energy Holdings Inc. (OTC:$GREH) Accelerates Expansion with $400K EV Infrastructure Incentive and Launch of Tempe Hilton Project - Showcasing Debt-Free ESCO Model Amid Explosive Sector Grow
-
AISIX Solutions Inc. Announces Wildfire Risk Intelligence Pilot with Leading Canadian Insurance Brokerage
-
PostcardMania Selected to Beta Test New Konica Minolta Digital Inkjet Printing Press, One of Only Two in North America
-
CSX names Kevin Boone CFO, promotes Maryclare Kenney to chief commercial officer
-
CSX Announces New Leadership Appointments
-
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
-
Northstar Announces Strategic Financing to Advance Surgical Mining of High-Grade Copper at Cam Copper Project
-
SGTM’s Water Less Garden™ Soil Launches on Amazon – A New Era of Sustainable Gardening Begins
-
Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics
-
Blazpay Presale Raises Over $868K While Ethereum and XRP Navigate Market Upswing
-
AbbVie's upadacitinib meets vitiligo study endpoints
-
AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo
-
Charles Schwab Provides 1+ Million Meals and Nonprofit Grants During Annual Season of Giving
-
Signal Advance(R) (OTC:SIGL) Hits Another Cybersecurity Milestone: Validates AI Resistant Analog Encryption
-
Conduent to Report Third-Quarter 2025 Financial Results on Nov. 7, 2025
-
Anavex reports long-term cognitive benefits from blarcamesine in alzheimer's trial
-
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
-
Coppernico Metals Expands Concessions at Sombrero
-
Aclaris Therapeutics to Participate in Three November Healthcare Conferences
-
Pleasing International Launches RWA Platform “Pleasing Golden,” Introducing Tokenized Gold (PGOLD) and Synthetic Dollar (PUSD)
-
Extreme Networks Reports First Quarter Fiscal Year 2026 Financial Results
-
LillyDirect partners with Walmart for Zepbound pickup option
-
Merck and Eisai discontinue liver cancer trial after survival endpoint missed
-
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
-
Blackstone Mortgage Trust Reports Third-Quarter 2025 Results
-
Ionis reports third quarter 2025 financial results and highlights progress on key programs
-
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
-
LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
-
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
-
Blackbaud Announces 2025 Third Quarter Results
-
European Commission approves Merck's KEYTRUDA for head and neck cancer treatment
-
European Commission Approves KEYTRUDA® (pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CP
-
Parsons wins $56 million Diriyah project contract in Saudi Arabia
-
PIF-Backed Diriyah Company Awards Parsons $56 million (SAR 210 million) Contract for Design and Construction Supervision in Saudi Arabia
-
Avantor® Reports Third Quarter 2025 Results
-
Sonoma Biotherapeutics Announces Positive Interim Safety and Efficacy Data from Phase 1 REGULATE-RA Study of SBT-77-7101 in Refractory Rheumatoid Arthritis
-
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
-
Blazpay’s Audited Crypto Presale 2025 Surges Past $925K — Less Than 5 Days Before Next Price Jump
-
14-year-old Combines Origami and Physics to Engineer Foldable Structures for Disaster Relief Shelters; Wins $25,000 Top Award at Thermo Fisher Scientific Junior Innovators Challenge
-
Anti-Hindu Event at Rutgers Draws Community Outrage, Congressional Concerns and Protest
-
UT Health San Antonio recognized among nation's top 100 oncology programs
-
22nd Century Announces Receipt of $9.5 Million from Settlement of Insurance Claim
-
Rapid Micro Biosystems to Announce Third Quarter 2025 Financial Results on November 7, 2025
-
SeaFi Launches $ 200,000 IDO for Adix ($ADIX) with Whitelist and Reward Campaigns Active Until November 5th
-
FIRST RESPONDERS CHILDREN'S FOUNDATION HONORS FIRST RESPONDER HEROES AT SIXTH ANNUAL NATIONAL FIRST RESPONDERS DAY CELEBRATION
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

